Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1976 1
1978 2
1980 1
1981 1
1984 1
1985 1
1986 2
1988 1
1989 5
1990 5
1991 2
1994 3
1995 6
1996 7
1997 6
1998 12
1999 9
2000 13
2001 13
2002 9
2003 12
2004 15
2005 16
2006 17
2007 21
2008 18
2009 9
2010 11
2011 14
2012 12
2013 12
2014 12
2015 12
2016 6
2017 7
2018 3
2019 7
2020 5
2021 8
2022 8
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Results by year

Filters applied: . Clear all
Page 1
The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.
Taranto-Montemurro L, Messineo L, Sands SA, Azarbarzin A, Marques M, Edwards BA, Eckert DJ, White DP, Wellman A. Taranto-Montemurro L, et al. Am J Respir Crit Care Med. 2019 May 15;199(10):1267-1276. doi: 10.1164/rccm.201808-1493OC. Am J Respir Crit Care Med. 2019. PMID: 30395486 Free PMC article. Clinical Trial.
Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic (oxybutynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (secondary outcome) in peo …
Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic …
Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial.
Berger M, Solelhac G, Marchi NA, Dussez R, Bradley B, Lecciso G, Heiniger G, Bayon V, Van Den Broecke S, Haba-Rubio J, Siclari F, Heinzer R. Berger M, et al. Sleep. 2023 Jul 11;46(7):zsad051. doi: 10.1093/sleep/zsad051. Sleep. 2023. PMID: 36861433 Clinical Trial.
The present study aimed to evaluate the effect of 1 week of 5 mg oxybutynin and 6 mg reboxetine (oxy-reb) on OSA versus placebo. METHODS: We performed a randomized, placebo-controlled, double-blind, crossover trial comparing the effect of 1 week of oxy-reb versus 1 week of …
The present study aimed to evaluate the effect of 1 week of 5 mg oxybutynin and 6 mg reboxetine (oxy-reb) on OSA versus placebo. METH …
A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin.
Casselini CM, Parson HK, Frizzi KE, Marquez A, Smith DR, Guernsey L, Nemmani R, Tayarani A, Jolivalt CG, Weaver J, Fernyhough P, Vinik AI, Calcutt NA. Casselini CM, et al. Acta Neuropathol. 2024 Mar 25;147(1):60. doi: 10.1007/s00401-024-02710-4. Acta Neuropathol. 2024. PMID: 38526612 Clinical Trial.
Subjects received daily topical treatment with 3% oxybutynin gel or placebo for 6 months. The a priori designated primary endpoint, significant change in intra-epidermal nerve fibre density (IENFD) in skin biopsies taken before and after 20 weeks of treatments, was met by …
Subjects received daily topical treatment with 3% oxybutynin gel or placebo for 6 months. The a priori designated primary endpoint, s …
The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome.
Combs D, Edgin J, Hsu CH, Bottrill K, Van Vorce H, Gerken B, Matloff D, La Rue S, Parthasarathy S. Combs D, et al. J Clin Sleep Med. 2023 Dec 1;19(12):2065-2073. doi: 10.5664/jcsm.10764. J Clin Sleep Med. 2023. PMID: 37555595 Clinical Trial.
Participants received low-dose ato-oxy (0.5 mg/kg atomoxetine and 5 mg oxybutynin) and high-dose ato-oxy (1.2 mg/kg atomoxetine and 5 mg oxybutynin) for 1 month in random order. ...CITATION: Combs D, Edgin J, Hsu C-H, et al. The combination of atomoxetine and oxy …
Participants received low-dose ato-oxy (0.5 mg/kg atomoxetine and 5 mg oxybutynin) and high-dose ato-oxy (1.2 mg/kg atomoxetine and 5 …
Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial.
Yokoyama O, Yamaguchi A, Yoshida M, Yamanishi T, Ishizuka O, Seki N, Takahashi S, Yamaguchi O, Higo N, Minami H, Masegi Y. Yokoyama O, et al. Int J Urol. 2015 Jul;22(7):684-8. doi: 10.1111/iju.12755. Epub 2015 Mar 17. Int J Urol. 2015. PMID: 25782032 Clinical Trial.
OBJECTIVES: To investigate the efficacy of a once-daily oxybutynin patch for nocturia, and its influence on sleep quality in patients with overactive bladder. ...The number of nocturia episodes decreased by 0.66 in the oxybutynin patch group versus 0.51 in the place …
OBJECTIVES: To investigate the efficacy of a once-daily oxybutynin patch for nocturia, and its influence on sleep quality in patients …
Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial.
Simon JA, Gaines T, LaGuardia KD; Extended-Release Oxybutynin Therapy for VMS Study Group. Simon JA, et al. Menopause. 2016 Nov;23(11):1214-1221. doi: 10.1097/GME.0000000000000773. Menopause. 2016. PMID: 27760081 Clinical Trial.
Mean changes in severity (scale 0-3) in the oxybutynin and placebo groups were -1.27 and -0.30, respectively, at week 12. At the end of treatment, 73% of women in the oxybutynin group and 26.1% in the placebo group rated symptom improvement "much better" (P 0.001). …
Mean changes in severity (scale 0-3) in the oxybutynin and placebo groups were -1.27 and -0.30, respectively, at week 12. At the end …
One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo-controlled Trial.
Aishah A, Loffler KA, Toson B, Mukherjee S, Adams RJ, Altree TJ, Ainge-Allen HW, Yee BJ, Grunstein RR, Carberry JC, Eckert DJ. Aishah A, et al. Ann Am Thorac Soc. 2023 Apr;20(4):584-595. doi: 10.1513/AnnalsATS.202206-492OC. Ann Am Thorac Soc. 2023. PMID: 36538809 Clinical Trial.
Objectives: To determine the safety, tolerability, and potential efficacy of longer term use of different doses of the noradrenergic agent atomoxetine combined with the antimuscarinic oxybutynin (ato-oxy). Methods: Thirty-nine people with predominantly severe OSA received …
Objectives: To determine the safety, tolerability, and potential efficacy of longer term use of different doses of the noradrenergic agent a …
Comparison of the Efficacy of Tolterodine versus Oxybutynin in the Treatment of Children with Desmopressin-Resistant Enuresis: A Randomized Controlled Clinical Trial.
Ezodin N, Sarouei M, Khademlo M, Milani SH, Yousefi S, Mohammadjafari H. Ezodin N, et al. Ethiop J Health Sci. 2023 Jul;33(4):611-620. doi: 10.4314/ejhs.v33i4.7. Ethiop J Health Sci. 2023. PMID: 38784212 Free PMC article. Clinical Trial.
This difference between the groups was not statistically significant. Seven patients (23%) in the Oxybutynin group and 13 patients (34%) in the Tolterodine group reported a lack of response to treatment, a difference that also lacked statistical significance. ...However, n …
This difference between the groups was not statistically significant. Seven patients (23%) in the Oxybutynin group and 13 patients (3 …
Combination pharmacological therapy targeting multiple mechanisms of sleep apnoea: a randomised controlled cross-over trial.
Sands SA, Collet J, Gell LK, Calianese N, Hess LB, Vena D, Azarbarzin A, Bertisch SM, Landry S, Thomson L, Joosten SA, Hamilton GS, Edwards BA. Sands SA, et al. Thorax. 2024 Feb 15;79(3):259-268. doi: 10.1136/thorax-2023-220184. Thorax. 2024. PMID: 38286618 Clinical Trial.
RATIONALE: Acetazolamide and atomoxetine-plus-oxybutynin ('AtoOxy') can improve obstructive sleep apnoea (OSA) by stabilising ventilatory control and improving dilator muscle responsiveness respectively. ...
RATIONALE: Acetazolamide and atomoxetine-plus-oxybutynin ('AtoOxy') can improve obstructive sleep apnoea (OSA) by stabilising ventila …
Initial study of transdermal oxybutynin for treating hyperhidrosis.
Millán-Cayetano JF, Del Boz J, Toledo-Pastrana T, Nieto-Guindo M, García-Montero P, de Troya-Martín M. Millán-Cayetano JF, et al. J Dermatol. 2017 Jun;44(6):717-720. doi: 10.1111/1346-8138.13748. Epub 2017 Jan 20. J Dermatol. 2017. PMID: 28106275 Clinical Trial.
Oral oxybutynin for treating hyperhidrosis is effective and safe. Its side-effects are mild but frequent so we consider whether transdermal oxybutynin (considered to have a better side-effect profile) could be an alternative for treating hyperhidrosis. ...The absenc …
Oral oxybutynin for treating hyperhidrosis is effective and safe. Its side-effects are mild but frequent so we consider whether trans …
312 results